These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Correction of a mineralization defect by overexpression of a wild-type cDNA for COL1A1 in marrow stromal cells (MSCs) from a patient with osteogenesis imperfecta: a strategy for rescuing mutations that produce dominant-negative protein defects. Pochampally RR; Horwitz EM; DiGirolamo CM; Stokes DS; Prockop DJ Gene Ther; 2005 Jul; 12(14):1119-25. PubMed ID: 15815702 [TBL] [Abstract][Full Text] [Related]
5. Gene therapy approaches for osteogenesis imperfecta. Niyibizi C; Wang S; Mi Z; Robbins PD Gene Ther; 2004 Feb; 11(4):408-16. PubMed ID: 14724682 [TBL] [Abstract][Full Text] [Related]
6. Knocking out the bad allele. Garofalo S; Quarto R Gene Ther; 2004 Sep; 11(17):1301-2. PubMed ID: 15229627 [No Abstract] [Full Text] [Related]
8. Antisense oligodeoxynucleotides selectively suppress expression of the mutant alpha 2(I) collagen allele in type IV osteogenesis imperfecta fibroblasts. A molecular approach to therapeutics of dominant negative disorders. Wang Q; Marini JC J Clin Invest; 1996 Jan; 97(2):448-54. PubMed ID: 8567966 [TBL] [Abstract][Full Text] [Related]
9. Gene symbol: COL1A1. Disease: Osteogenesis imperfecta type I. Schafer IA; Stein J; Hyland JC; Clark B Hum Genet; 2004 Mar; 114(4):404. PubMed ID: 15046069 [No Abstract] [Full Text] [Related]
10. Gene targeting in stem cells from individuals with osteogenesis imperfecta. Chamberlain JR; Schwarze U; Wang PR; Hirata RK; Hankenson KD; Pace JM; Underwood RA; Song KM; Sussman M; Byers PH; Russell DW Science; 2004 Feb; 303(5661):1198-201. PubMed ID: 14976317 [TBL] [Abstract][Full Text] [Related]
11. Enhanced intracellular availability and survival of hammerhead ribozymes increases target ablation in a cellular model of osteogenesis imperfecta. Smicun Y; Kilpatrick MW; Florer J; Toudjarska I; Wu G; Wenstrup RJ; Tsipouras P Gene Ther; 2003 Nov; 10(24):2005-12. PubMed ID: 14566359 [TBL] [Abstract][Full Text] [Related]
12. Molecular basis of osteogenesis imperfecta and related disorders of bone. Prockop DJ; Kuivaniemi H; Tromp G Clin Plast Surg; 1994 Jul; 21(3):407-13. PubMed ID: 7924138 [TBL] [Abstract][Full Text] [Related]
13. Filling the gaps: osteogenesis imperfecta. Graul AI Drug News Perspect; 2005; 18(6):400-1. PubMed ID: 16247517 [No Abstract] [Full Text] [Related]
15. Osteogenesis imperfecta and its molecular diagnosis by determination of mutations of type I collagen genes. Tedeschi E; Antoniazzi F; Venturi G; Zamboni G; Tatò L Pediatr Endocrinol Rev; 2006 Sep; 4(1):40-6. PubMed ID: 17021582 [TBL] [Abstract][Full Text] [Related]
16. [Osteogenesis imperfecta--a congenital brittleness of bones]. Kaitila I; Kuurila K; Kallio P Duodecim; 2001; 117(21):2195-202. PubMed ID: 12184207 [No Abstract] [Full Text] [Related]
17. Osteogenesis imperfecta: clinical, biochemical and molecular findings. Venturi G; Tedeschi E; Mottes M; Valli M; Camilot M; Viglio S; Antoniazzi F; Tatò L Clin Genet; 2006 Aug; 70(2):131-9. PubMed ID: 16879195 [TBL] [Abstract][Full Text] [Related]
18. [Gene errors as a cause of rare and common connective tissue diseases]. Ala-Kokko L; Kuivaniemi H Duodecim; 1994; 110(7):731-9. PubMed ID: 8542828 [No Abstract] [Full Text] [Related]
19. Mineral changes in a transgenic mouse model for osteogenesis imperfecta. Cassella JP; Pereira R; Prockop DJ; Ali SY Br J Biomed Sci; 1996 Jun; 53(2):108-15. PubMed ID: 8757687 [TBL] [Abstract][Full Text] [Related]